Idex (IEX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, Idex (IEX) reported revenue of $878.7 million, up 10.1% over the same period last year. EPS came in at $2.03, compared to $1.90 in the year-ago quarter.

The reported revenue represents a surprise of +2.37% over the Zacks Consensus Estimate of $858.37 million. With the consensus EPS estimate being $1.93, the EPS surprise was +5.18%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Idex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales - Organic impact - YoY change: 5% versus 2.4% estimated by two analysts on average.
• Net Sales- Fluid & Metering Technologies (FMT): $317.1 million versus $305.75 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
• Intersegment sales eliminations: $-1.3 million versus $-1.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -18.8% change.
• Net Sales- Fire & Safety/Diversified Products (FSDP): $181.9 million compared to the $190.45 million average estimate based on three analysts. The reported number represents a change of -3.2% year over year.
• Net Sales- Health & Science Technologies (HST): $381 million compared to the $362.99 million average estimate based on three analysts. The reported number represents a change of +22.5% year over year.
• Adjusted EBITDA- Fluid & Metering Technologies (FMT): $106.8 million versus $103.59 million estimated by three analysts on average.
• Adjusted EBITDA- Corporate: $-21.7 million versus the three-analyst average estimate of $-26.16 million.
• Adjusted EBITDA- Fire & Safety/Diversified Products (FSDP): $49.3 million versus the three-analyst average estimate of $55.1 million.
• Adjusted EBITDA- Health & Science Technologies (HST): $105.4 million versus $95.53 million estimated by three analysts on average.

View all Key Company Metrics for Idex here>>>

Shares of Idex have returned +2.6% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
IDEX Corporation (IEX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research